Summary of Connections (With Links) Team is looking good! TORONTO, Feb. 28, 2018 (GLOBE NEWSWIRE) -- BELGRAVIA CAPITAL INTERNATIONAL INC. (CSE:BLGV) (
BLGVF) (“Belgravia Capital”, “Belgravia”, or the “Company”) is pleased to announce the execution of a binding letter of intent with R&D Pharma Corp. (“RDP”) for the investment of one million Canadian dollars (Cdn$1,000,000) at a price of $0.25 per common share. RDP is a Canadian private corporation developing a vertically integrated medicinal cannabis business in Jamaica. The completion of the investment transaction is subject to the completion of due diligence.
https://finance.yahoo.com/news/belgravia-capital-signs-binding-letter-120000098.html;_ylc=X1MDMTE5Nzc4NDE4NQRfZXgDMQRfeXJpZANlcTgzbHBwZDlkNzkyBGcDZFhWcFpEeHVjejQyT0dNME9ERmlaQzB6T1dKakxUTTBNalF0T1RReU1TMDNPVGMyWWpkbFpUWTVObUoxZFdsa1BHNXpQa0pNUjFZdQ0KUTA0PQ0KBGxhbmcDZW4tVVMEb3JpZ19sYW5nA2VuLUdCBG9yaWdfcmVnaW9uA0FMBHBvcwMwBHJlZ2lvbgNVUwRzeW1ib2wDQkxHVi5DTg--?.tsrc=applewf Executive chairman of Medicanja Dr Henry Lowe on Friday confirmed to the Jamaica Observer that the company is looking to list on both the Canadian Securities Exchange (CSE) junior market and the Jamaica Stock Exchange by the first quarter of 2018. CEO of R&D Pharma in Canada Derrick Lewis, while tight-lipped on the details of the initial public offering, told
Sunday Finance that the funds raised will be used to build out the corporate structure of Medicanja in Jamaica and Canada.
The company is allowed to raise a maximum of CAN$7 million from the stock market. The listing of Medicanja will bring the total of marijuana-linked companies to 13 since the start of the year, according to the CSE website. It will, however, be the first of its kind to list on the local market.
Still, Jamaica and Canada are not the only markets Lowe is eyeing. Plans are well advanced for listing on the Australian and United States stock markets as well. Canada, however, is set to become one of the first advanced industrialised nations to legalise and regulate marijuana.
Under the proposed legislation, the Canadian government would license the growing of cannabis by tightly regulated producers and set standards for potency and penalties for abuse. The provinces would decide on methods for distribution.
Just Thursday, Medicanja launched six products, namely canjaCol, relevium cream, relevium spray, canjarub, somnican and tivasat to be used for the treatment of pains, swelling and strains. The products, which have been in production since 2013, will be available in more than 20 pharmacies islandwide by next week.
The launch follows on the unveiling of products designed to treat and manage some 84 maladies, including Ganja Relief, Ganja Salve, Ganjaflam, Ganja Col, Ganja Rub, Ganja Pain and Ganja Sure.
Taboola
Lowe has also been recognised for development of Cresorol, an anti-cancer drug made from marijuana predicted to rake in annual sales of US$250 million.
He noted that once properly organised, the local market could see sustained earnings of US$1.5 billion per year in the next three years, revenues that would grow to surpass the tourism industry and even remittance inflows.
“When Medicanja was set up, I promised the people of Jamaica that not everybody who thought about getting in the medical cannabis business would have the interest in getting into the business directly themselves. Consequently, Medicanja was established to offer the vehicle for them to invest and get involved in industry,” he told the
Jamaica Observer.
https://www.jamaicaobserver.com/sunday-finance/medicanja-to-list-on-canadian-jamaican-stock-markets-q1-2018_116066?profile=1442&template=MobileArticle
R&D Pharma Corp., a Canadian private company, is building a vertically integrated medical cannabis business in the Country of Jamaica. Jamaica has sophisticated medical cannabis laws in place consistent with the best in class laws of Canada and Israel. Further, well recognized international regulated cannabis production and distribution companies are establishing footholds in Jamaica due to the recognized quality of the strains and, also Jamaica's history of medical research in this space. For example, Dr. Henry Lowe of Kingston, Jamaica, a specialist in medicinal chemistry, a chemistry-based discipline involving biological, medical and pharmaceutical sciences, has contributed 50 years to the fields of biotechnology ethical drug development, including drug regulatory validated cannabis sativa products, for conditions such as nausea, pain, appetite stimulation, motion sickness, inflammation, and high ocular pressure which can lead to glaucoma.
The provisions of the Letter of Intent with R&D Pharma include:
• R&D will provide validated input data regarding concentration of Cannabinoids in products, and other active ingredients, and levels of any impurities which will be required to be consistent with established standards;
• R&D will provide references on the blockchain will be provided to off-chain documents including hash indexes to reports of independent analytical labs for microbiology, heavy metals, pesticides, and metabolites;
• Belgravia will invite R&D to be a permissioned node on the distributed blockchain; and
• Revenue sharing models will be negotiated in due course, and as business cases are further evaluated, and a significant number
• of additional industry players, regulators, and consumer conduits are established through social media marketing and other consumer outreach forums.
https://www.nasdaq.com/press-release/belgravia-capital-international-announces-loi-with-rd-pharma-corp-20180104-00208
Lowe has also been recognised for development of Cresorol, an anti-cancer drug made from marijuana predicted to rake in annual sales of US$250 million.
He noted that once properly organised, the local market could see sustained earnings of US$1.5 billion per year in the next three years, revenues that would grow to surpass the tourism industry and even remittance inflows.
“When Medicanja was set up, I promised the people of Jamaica that not everybody who thought about getting in the medical cannabis business would have the interest in getting into the business directly themselves. Consequently, Medicanja was established to offer the vehicle for them to invest and get involved in industry,” he told the
Jamaica Observer.
https://www.jamaicaobserver.com/sunday-finance/medicanja-to-list-on-canadian-jamaican-stock-markets-q1-2018_116066?profile=1442 KINGSTON, Jamaica — A drug developed by Jamaican scientist Dr Henry Lowe and his team of researchers to treat acute myeloid leukemia (AML), has been granted orphan-drug designation by the United States Food and Drug Administration (FDA).
News of the development was made public a short while ago by Dr Lowe who described it as historic and said it holds the potential to earn Jamaica more than US$250 million within three years in the US market alone.
“As far as I am aware, this is the first time that anyone from a developing country like Jamaica has been able to achieve this feat of starting from the isolation of a bioactive molecule and working it up to provide a new drug from scratch, which is recognised by the FDA, which is the world leading food and drug regulator and approval agency,” Lowe told guests at a function at his Eden Gardens Wellness Resort and Spa in Kingston.
Lowe, known for using the properties of Jamaican plants, particularly ball moss and cannabis, in his cancer research, was notified of the approval last month.
The FDA, in a letter to Flavocure Biotech, a company formed by Dr Lowe, stated that it was granting the company's request for the drug to be designated orphan drug status pursuant to section 526 of the Federal Food, Drug, and Cosmetic Act.
Significantly, the FDA stated that the designation granted is broader then the indication proposed in the company's request.
The FDA explains on its website that the Orphan Drug Act (ODA) provides for granting special status to a drug or biological product to treat a rare disease or condition upon request of a sponsor.
Taboola
“This status is referred to as orphan designation (or sometimes “orphan status”). For a drug to qualify for orphan designation both the drug and the disease or condition must meet certain criteria specified in the ODA and FDA's implementing regulations,” the agency states.
This afternoon, Dr Lowe explained that the drug, which has the trade name Cresorol, is a non-cannabinoid developed from the cannabis plant.
https://www.jamaicaobserver.com/latestnews/Jamaican_scientist_makes_FDA_breakthrough_with_drug_to_treat_myeloid_leukemia?profile=1228